The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
Identifieur interne : 000453 ( Main/Exploration ); précédent : 000452; suivant : 000454The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
Auteurs : Samuel Aballéa [Royaume-Uni] ; Jeremy Chancellor ; Monique Martin ; Peter Wutzler ; Fabrice Carrat ; Roberto Gasparini ; Joao Toniolo-Neto ; Michael Drummond ; Milton WeinsteinSource :
- Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [ 1098-3015 ]
Descripteurs français
- KwdFr :
- Adulte d'âge moyen (MeSH), Allemagne (épidémiologie), Analyse coût-bénéfice (MeSH), Années de vie ajustées sur la qualité (MeSH), Brésil (épidémiologie), Espérance de vie (MeSH), Facteurs âges (MeSH), Femelle (MeSH), France (épidémiologie), Grippe humaine (prévention et contrôle), Grippe humaine (économie), Grippe humaine (épidémiologie), Humains (MeSH), Internationalité (MeSH), Italie (épidémiologie), Modèles économétriques (MeSH), Mâle (MeSH), Politique de santé (économie), Programmes de vaccination (économie), Techniques d'aide à la décision (MeSH), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (économie).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- prévention et contrôle : Grippe humaine.
- économie : Grippe humaine, Politique de santé, Programmes de vaccination, Vaccins antigrippaux.
- épidémiologie : Allemagne, Brésil, France, Grippe humaine, Italie.
- Adulte d'âge moyen, Analyse coût-bénéfice, Années de vie ajustées sur la qualité, Espérance de vie, Facteurs âges, Femelle, Humains, Internationalité, Modèles économétriques, Mâle, Techniques d'aide à la décision.
- Wicri :
English descriptors
- KwdEn :
- Age Factors (MeSH), Brazil (epidemiology), Cost-Benefit Analysis (MeSH), Decision Support Techniques (MeSH), Female (MeSH), France (epidemiology), Germany (epidemiology), Health Policy (economics), Humans (MeSH), Immunization Programs (economics), Influenza Vaccines (administration & dosage), Influenza Vaccines (economics), Influenza, Human (economics), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Internationality (MeSH), Italy (epidemiology), Life Expectancy (MeSH), Male (MeSH), Middle Aged (MeSH), Models, Econometric (MeSH), Quality-Adjusted Life Years (MeSH).
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , economics : Influenza Vaccines.
- geographic , epidemiology : Brazil, France, Germany, Italy.
- economics : Health Policy, Immunization Programs, Influenza, Human.
- epidemiology : Influenza, Human.
- prevention & control : Influenza, Human.
- Age Factors, Cost-Benefit Analysis, Decision Support Techniques, Female, Humans, Internationality, Life Expectancy, Male, Middle Aged, Models, Econometric, Quality-Adjusted Life Years.
Abstract
OBJECTIVES
Routine influenza vaccination is currently recommended in several countries for people aged more than 60 or 65 years or with high risk of complications. A lower age threshold of 50 years has been recommended in the United States since 1999. To help policymakers consider whether such a policy should be adopted more widely, we conducted an economic evaluation of lowering the age limit for routine influenza vaccination to 50 years in Brazil, France, Germany, and Italy.
METHODS
The probabilistic model was designed to compare in a single season the costs and clinical outcomes associated with two alternative vaccination policies for persons aged 50 to 64 years: reimbursement only for people at high risk of complications (current policy), and reimbursement for all individuals in this age group (proposed policy). Two perspectives were considered: third-party payer (TPP) and societal. Model inputs were obtained primarily from the published literature and validated through expert opinion. The historical distribution of annual influenza-like illness (ILI) incidence was used to simulate the uncertain incidence in any given season. We estimated gains in unadjusted and quality-adjusted life expectancy, and the cost per quality-adjusted life-year (QALY) gained. Deterministic and probabilistic sensitivity analyses were conducted.
RESULTS
Comparing the proposed to the current policy, the estimated mean costs per QALY gained were R$4,100, EURO 13,200, EURO 31,400 and EURO 15,700 for Brazil, France, Germany, and Italy, respectively, from a TPP perspective. From the societal perspective, the age-based policy is predicted to yield net cost savings in Germany and Italy, whereas the cost per QALY decreased to R$2800 for Brazil and EURO 8000 for France. The results were particularly sensitive to the ILI incidence rate, vaccine uptake, influenza fatality rate, and the costs of administering vaccination. Assuming a cost-effectiveness threshold ratio of EURO 50,000 per QALY gained, the probabilities of the new policy being cost-effective were 94% and 95% for France, 72% and near 100% for Germany, and 89% and 99% for Italy, from the TPP and societal perspectives, respectively.
CONCLUSIONS
Extending routine influenza vaccination to people more than 50 years of age is likely to be cost-effective in all four countries studied.
DOI: 10.1111/j.1524-4733.2006.00157.x
PubMed: 17391419
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.</title><author><name sortKey="Aballea, Samuel" sort="Aballea, Samuel" uniqKey="Aballea S" first="Samuel" last="Aballéa">Samuel Aballéa</name><affiliation wicri:level="1"><nlm:affiliation>i3 Innovus, Uxbridge, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>i3 Innovus, Uxbridge</wicri:regionArea><wicri:noRegion>Uxbridge</wicri:noRegion></affiliation></author><author><name sortKey="Chancellor, Jeremy" sort="Chancellor, Jeremy" uniqKey="Chancellor J" first="Jeremy" last="Chancellor">Jeremy Chancellor</name></author><author><name sortKey="Martin, Monique" sort="Martin, Monique" uniqKey="Martin M" first="Monique" last="Martin">Monique Martin</name></author><author><name sortKey="Wutzler, Peter" sort="Wutzler, Peter" uniqKey="Wutzler P" first="Peter" last="Wutzler">Peter Wutzler</name></author><author><name sortKey="Carrat, Fabrice" sort="Carrat, Fabrice" uniqKey="Carrat F" first="Fabrice" last="Carrat">Fabrice Carrat</name></author><author><name sortKey="Gasparini, Roberto" sort="Gasparini, Roberto" uniqKey="Gasparini R" first="Roberto" last="Gasparini">Roberto Gasparini</name></author><author><name sortKey="Toniolo Neto, Joao" sort="Toniolo Neto, Joao" uniqKey="Toniolo Neto J" first="Joao" last="Toniolo-Neto">Joao Toniolo-Neto</name></author><author><name sortKey="Drummond, Michael" sort="Drummond, Michael" uniqKey="Drummond M" first="Michael" last="Drummond">Michael Drummond</name></author><author><name sortKey="Weinstein, Milton" sort="Weinstein, Milton" uniqKey="Weinstein M" first="Milton" last="Weinstein">Milton Weinstein</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007 Mar-Apr</date><idno type="RBID">pubmed:17391419</idno><idno type="pmid">17391419</idno><idno type="doi">10.1111/j.1524-4733.2006.00157.x</idno><idno type="wicri:Area/Main/Corpus">000476</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000476</idno><idno type="wicri:Area/Main/Curation">000476</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000476</idno><idno type="wicri:Area/Main/Exploration">000476</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.</title><author><name sortKey="Aballea, Samuel" sort="Aballea, Samuel" uniqKey="Aballea S" first="Samuel" last="Aballéa">Samuel Aballéa</name><affiliation wicri:level="1"><nlm:affiliation>i3 Innovus, Uxbridge, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>i3 Innovus, Uxbridge</wicri:regionArea><wicri:noRegion>Uxbridge</wicri:noRegion></affiliation></author><author><name sortKey="Chancellor, Jeremy" sort="Chancellor, Jeremy" uniqKey="Chancellor J" first="Jeremy" last="Chancellor">Jeremy Chancellor</name></author><author><name sortKey="Martin, Monique" sort="Martin, Monique" uniqKey="Martin M" first="Monique" last="Martin">Monique Martin</name></author><author><name sortKey="Wutzler, Peter" sort="Wutzler, Peter" uniqKey="Wutzler P" first="Peter" last="Wutzler">Peter Wutzler</name></author><author><name sortKey="Carrat, Fabrice" sort="Carrat, Fabrice" uniqKey="Carrat F" first="Fabrice" last="Carrat">Fabrice Carrat</name></author><author><name sortKey="Gasparini, Roberto" sort="Gasparini, Roberto" uniqKey="Gasparini R" first="Roberto" last="Gasparini">Roberto Gasparini</name></author><author><name sortKey="Toniolo Neto, Joao" sort="Toniolo Neto, Joao" uniqKey="Toniolo Neto J" first="Joao" last="Toniolo-Neto">Joao Toniolo-Neto</name></author><author><name sortKey="Drummond, Michael" sort="Drummond, Michael" uniqKey="Drummond M" first="Michael" last="Drummond">Michael Drummond</name></author><author><name sortKey="Weinstein, Milton" sort="Weinstein, Milton" uniqKey="Weinstein M" first="Milton" last="Weinstein">Milton Weinstein</name></author></analytic><series><title level="j">Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</title><idno type="ISSN">1098-3015</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors (MeSH)</term><term>Brazil (epidemiology)</term><term>Cost-Benefit Analysis (MeSH)</term><term>Decision Support Techniques (MeSH)</term><term>Female (MeSH)</term><term>France (epidemiology)</term><term>Germany (epidemiology)</term><term>Health Policy (economics)</term><term>Humans (MeSH)</term><term>Immunization Programs (economics)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (economics)</term><term>Influenza, Human (economics)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Internationality (MeSH)</term><term>Italy (epidemiology)</term><term>Life Expectancy (MeSH)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Models, Econometric (MeSH)</term><term>Quality-Adjusted Life Years (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term><term>Allemagne (épidémiologie)</term><term>Analyse coût-bénéfice (MeSH)</term><term>Années de vie ajustées sur la qualité (MeSH)</term><term>Brésil (épidémiologie)</term><term>Espérance de vie (MeSH)</term><term>Facteurs âges (MeSH)</term><term>Femelle (MeSH)</term><term>France (épidémiologie)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (économie)</term><term>Grippe humaine (épidémiologie)</term><term>Humains (MeSH)</term><term>Internationalité (MeSH)</term><term>Italie (épidémiologie)</term><term>Modèles économétriques (MeSH)</term><term>Mâle (MeSH)</term><term>Politique de santé (économie)</term><term>Programmes de vaccination (économie)</term><term>Techniques d'aide à la décision (MeSH)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (économie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Brazil</term><term>France</term><term>Germany</term><term>Italy</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Health Policy</term><term>Immunization Programs</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Grippe humaine</term><term>Politique de santé</term><term>Programmes de vaccination</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Allemagne</term><term>Brésil</term><term>France</term><term>Grippe humaine</term><term>Italie</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Age Factors</term><term>Cost-Benefit Analysis</term><term>Decision Support Techniques</term><term>Female</term><term>Humans</term><term>Internationality</term><term>Life Expectancy</term><term>Male</term><term>Middle Aged</term><term>Models, Econometric</term><term>Quality-Adjusted Life Years</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Analyse coût-bénéfice</term><term>Années de vie ajustées sur la qualité</term><term>Espérance de vie</term><term>Facteurs âges</term><term>Femelle</term><term>Humains</term><term>Internationalité</term><term>Modèles économétriques</term><term>Mâle</term><term>Techniques d'aide à la décision</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Brésil</term><term>France</term><term>Allemagne</term><term>Italie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b></p><p>Routine influenza vaccination is currently recommended in several countries for people aged more than 60 or 65 years or with high risk of complications. A lower age threshold of 50 years has been recommended in the United States since 1999. To help policymakers consider whether such a policy should be adopted more widely, we conducted an economic evaluation of lowering the age limit for routine influenza vaccination to 50 years in Brazil, France, Germany, and Italy.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>The probabilistic model was designed to compare in a single season the costs and clinical outcomes associated with two alternative vaccination policies for persons aged 50 to 64 years: reimbursement only for people at high risk of complications (current policy), and reimbursement for all individuals in this age group (proposed policy). Two perspectives were considered: third-party payer (TPP) and societal. Model inputs were obtained primarily from the published literature and validated through expert opinion. The historical distribution of annual influenza-like illness (ILI) incidence was used to simulate the uncertain incidence in any given season. We estimated gains in unadjusted and quality-adjusted life expectancy, and the cost per quality-adjusted life-year (QALY) gained. Deterministic and probabilistic sensitivity analyses were conducted.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Comparing the proposed to the current policy, the estimated mean costs per QALY gained were R$4,100, EURO 13,200, EURO 31,400 and EURO 15,700 for Brazil, France, Germany, and Italy, respectively, from a TPP perspective. From the societal perspective, the age-based policy is predicted to yield net cost savings in Germany and Italy, whereas the cost per QALY decreased to R$2800 for Brazil and EURO 8000 for France. The results were particularly sensitive to the ILI incidence rate, vaccine uptake, influenza fatality rate, and the costs of administering vaccination. Assuming a cost-effectiveness threshold ratio of EURO 50,000 per QALY gained, the probabilities of the new policy being cost-effective were 94% and 95% for France, 72% and near 100% for Germany, and 89% and 99% for Italy, from the TPP and societal perspectives, respectively.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Extending routine influenza vaccination to people more than 50 years of age is likely to be cost-effective in all four countries studied.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17391419</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2007</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1098-3015</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><MedlineDate>2007 Mar-Apr</MedlineDate></PubDate></JournalIssue><Title>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</Title><ISOAbbreviation>Value Health</ISOAbbreviation></Journal><ArticleTitle>The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.</ArticleTitle><Pagination><MedlinePgn>98-116</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Routine influenza vaccination is currently recommended in several countries for people aged more than 60 or 65 years or with high risk of complications. A lower age threshold of 50 years has been recommended in the United States since 1999. To help policymakers consider whether such a policy should be adopted more widely, we conducted an economic evaluation of lowering the age limit for routine influenza vaccination to 50 years in Brazil, France, Germany, and Italy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The probabilistic model was designed to compare in a single season the costs and clinical outcomes associated with two alternative vaccination policies for persons aged 50 to 64 years: reimbursement only for people at high risk of complications (current policy), and reimbursement for all individuals in this age group (proposed policy). Two perspectives were considered: third-party payer (TPP) and societal. Model inputs were obtained primarily from the published literature and validated through expert opinion. The historical distribution of annual influenza-like illness (ILI) incidence was used to simulate the uncertain incidence in any given season. We estimated gains in unadjusted and quality-adjusted life expectancy, and the cost per quality-adjusted life-year (QALY) gained. Deterministic and probabilistic sensitivity analyses were conducted.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Comparing the proposed to the current policy, the estimated mean costs per QALY gained were R$4,100, EURO 13,200, EURO 31,400 and EURO 15,700 for Brazil, France, Germany, and Italy, respectively, from a TPP perspective. From the societal perspective, the age-based policy is predicted to yield net cost savings in Germany and Italy, whereas the cost per QALY decreased to R$2800 for Brazil and EURO 8000 for France. The results were particularly sensitive to the ILI incidence rate, vaccine uptake, influenza fatality rate, and the costs of administering vaccination. Assuming a cost-effectiveness threshold ratio of EURO 50,000 per QALY gained, the probabilities of the new policy being cost-effective were 94% and 95% for France, 72% and near 100% for Germany, and 89% and 99% for Italy, from the TPP and societal perspectives, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Extending routine influenza vaccination to people more than 50 years of age is likely to be cost-effective in all four countries studied.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aballéa</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>i3 Innovus, Uxbridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chancellor</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Monique</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wutzler</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Carrat</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Gasparini</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Toniolo-Neto</LastName><ForeName>Joao</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Drummond</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Weinstein</LastName><ForeName>Milton</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Value Health</MedlineTA><NlmUniqueID>100883818</NlmUniqueID><ISSNLinking>1098-3015</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003661" MajorTopicYN="N">Decision Support Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006291" MajorTopicYN="N">Health Policy</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017589" MajorTopicYN="N">Immunization Programs</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038622" MajorTopicYN="N">Internationality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008017" MajorTopicYN="N">Life Expectancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017059" MajorTopicYN="N">Models, Econometric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019057" MajorTopicYN="N">Quality-Adjusted Life Years</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>3</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>5</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>3</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17391419</ArticleId><ArticleId IdType="pii">S1098-3015(10)60458-5</ArticleId><ArticleId IdType="doi">10.1111/j.1524-4733.2006.00157.x</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Royaume-Uni</li></country></list><tree><noCountry><name sortKey="Carrat, Fabrice" sort="Carrat, Fabrice" uniqKey="Carrat F" first="Fabrice" last="Carrat">Fabrice Carrat</name><name sortKey="Chancellor, Jeremy" sort="Chancellor, Jeremy" uniqKey="Chancellor J" first="Jeremy" last="Chancellor">Jeremy Chancellor</name><name sortKey="Drummond, Michael" sort="Drummond, Michael" uniqKey="Drummond M" first="Michael" last="Drummond">Michael Drummond</name><name sortKey="Gasparini, Roberto" sort="Gasparini, Roberto" uniqKey="Gasparini R" first="Roberto" last="Gasparini">Roberto Gasparini</name><name sortKey="Martin, Monique" sort="Martin, Monique" uniqKey="Martin M" first="Monique" last="Martin">Monique Martin</name><name sortKey="Toniolo Neto, Joao" sort="Toniolo Neto, Joao" uniqKey="Toniolo Neto J" first="Joao" last="Toniolo-Neto">Joao Toniolo-Neto</name><name sortKey="Weinstein, Milton" sort="Weinstein, Milton" uniqKey="Weinstein M" first="Milton" last="Weinstein">Milton Weinstein</name><name sortKey="Wutzler, Peter" sort="Wutzler, Peter" uniqKey="Wutzler P" first="Peter" last="Wutzler">Peter Wutzler</name></noCountry><country name="Royaume-Uni"><noRegion><name sortKey="Aballea, Samuel" sort="Aballea, Samuel" uniqKey="Aballea S" first="Samuel" last="Aballéa">Samuel Aballéa</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeAllemagneV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000453 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000453 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeAllemagneV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:17391419
|texte= The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:17391419" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV4
| This area was generated with Dilib version V0.6.35. |  |